Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI)

Historical Holders from Q1 2014 to Q1 2025

Symbol
ITCI on Nasdaq
CUSIP
46116X101
Type / Class
Equity / COMMON STOCK
Shares outstanding
108M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
96.7M
Holdings value
$8.08B
% of all portfolios
0.011%
Grand Portfolio weight change
+0%
Number of holders
378
Number of buys
178
Number of sells
-163
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 2.5% $356M 2.7M FMR LLC Jan 31, 2025

Institutional Holders of Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 379K $49.9M -$21.2M $131.92 33
2024 Q4 96.7M $8.08B +$213M $83.52 378
2024 Q3 93.9M $6.89B -$164M $73.17 352
2024 Q2 96.4M $6.6B +$646M $68.49 370
2024 Q1 87.2M $6.04B -$120M $69.20 341
2023 Q4 88.1M $6.31B +$159M $71.62 322
2023 Q3 86M $4.49B +$121M $52.09 284
2023 Q2 83.3M $5.27B +$2.78M $63.32 280
2023 Q1 83.6M $4.53B +$29M $54.15 267
2022 Q4 83M $4.39B +$179K $52.92 277
2022 Q3 82.7M $3.85B +$73.4M $46.53 254
2022 Q2 80.2M $4.58B +$38.4M $57.08 249
2022 Q1 79.5M $4.86B +$736M $61.19 226
2021 Q4 67.9M $3.56B +$16.6M $52.34 193
2021 Q3 68.3M $2.55B +$46.2M $37.28 172
2021 Q2 67M $2.73B -$32.5M $40.82 178
2021 Q1 67.9M $2.3B +$35.4M $33.93 160
2020 Q4 67M $2.13B +$100M $31.80 172
2020 Q3 63.7M $1.63B +$384M $25.66 170
2020 Q2 48.8M $1.25B +$59.1M $25.67 145
2020 Q1 46.6M $716M +$139M $15.37 131
2019 Q4 38M $1.3B -$41.7M $34.31 130
2019 Q3 39M $292M -$5.07M $7.47 123
2019 Q2 38.4M $498M +$39.4M $12.98 125
2019 Q1 38.2M $465M +$8.14M $12.18 124
2018 Q4 37.9M $432M -$15.5M $11.39 125
2018 Q3 38.1M $827M -$21.7M $21.70 129
2018 Q2 38.6M $682M +$3.3M $17.67 124
2018 Q1 39.4M $829M +$31.4M $21.05 128
2017 Q4 37.6M $543M -$37.9M $14.48 128
2017 Q3 40.5M $637M +$153M $15.78 136
2017 Q2 30.9M $384M +$13.2M $12.42 98
2017 Q1 28.9M $469M +$47.1M $16.25 109
2016 Q4 29.7M $448M +$33.4M $15.09 124
2016 Q3 27.9M $425M -$109M $15.24 126
2016 Q2 30.1M $1.17B +$49M $38.82 138
2016 Q1 29.1M $808M +$7.28M $27.80 124
2015 Q4 28.5M $1.53B +$51.7M $53.79 131
2015 Q3 27.6M $1.1B +$382M $40.04 129
2015 Q2 17.8M $570M +$33.7M $31.95 91
2015 Q1 17M $405M +$112M $23.88 74
2014 Q4 12.2M $215M +$2.4M $17.65 46
2014 Q3 12.1M $166M -$574K $13.71 47
2014 Q2 12.1M $204M +$18M $16.86 55
2014 Q1 11M $201M +$200M $18.18 35